Will Eli Lilly's new weight loss drug Zepbound sell >$2B in the US by 2025? (first full year on the market)
Basic
5
Ṁ1249Feb 16
99%
chance
1D
1W
1M
ALL
This market will resolve to YES if Zepbound has sold at least $2 billion in the US after its first 4 full quarters on the market. The evaluation criteria will be Eli Lilly's Annual Report for FY 2024. This is expected to be available in February 2025.
This question is managed and resolved by Manifold.
Get
1,000and
3.00
1,0003.00Related questions
Related questions
Will a GLP-1 agonist diabetes / weight loss drug be the top bestselling drug in 2025?
30% chance
Will Jazz's Xywav drug sell >$1.4B in the US in 2024?
57% chance
Will a drug company pay >$1m in a class action suit based on their statements about their GLP1 inhibitor by 2026?
38% chance
Affordable weight loss drugs before 2030?
76% chance
Ozempic will NOT be the leading GLP-1 agonist by total $ US sales by December 31, 2025
48% chance
More than 10% of US citizens will be on prescription drugs for weight loss by 2031
63% chance
Will Pfizer announce a weight loss drug competing with Ozempic and Wygovy before 12/31/2024?
35% chance
Will Retatrutide (new obesity drug) be FDA approved by the end of 2025?
36% chance
Will Donald Trump ever take a GLP-1 agonist (eg Ozempic, Mounjaro, Wegovy, Zepbound, etc) for weight loss
65% chance
More than 30% of US citizens will be on prescription drugs for weight loss by 2031
22% chance